Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 19, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data present relates to a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.285 per share.
- Transaction Volume: 1,944.275 shares (aggregated).
Material Changes
The filing reports an increase in the notional interest in Ordinary Shares for Mr. P C Thomson, SVP of Communications & Government Affairs. This increase resulted from the re-investment of dividends paid on July 14, 2016, under the Company's 2009 Performance Share Plan. No material changes to the company's overall financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of a specific executive share transaction.
Investor Verification Points
- Verify the total shareholding of Mr. P C Thomson following this transaction to assess alignment with company performance.
- Confirm the dividend reinvestment terms of the 2009 Performance Share Plan.
- Note that this filing contains no operational or financial performance data; refer to the company's Form 20-F or interim reports for financial metrics.